

Clinics and Research Grants

MDA



Metroplex MDA Clinics

Children's Medical Center of Dallas
1935 Motor Street
Dallas, TX 75235
Susan Iannaccone, MD Director

Neurological Clinic Of Texas
7777 Forest Lane, Suite B-116
Dallas, TX 75230
Susan E. Hotz, MD Director

Texas Neurology, P.A.
6301 Gaston Ave., Ste. 200W
Dallas, TX 75214
Daragh Heitzman, MD Director

Texoma Neurology Associates
321 N. Highland
Suite 200
Sherman, TX 75092
Easwar M. Sundaram, Jr., MD, Director

University of Texas/SW Medical Center
SW Medical Center at Dallas
5323 Harry Hines Boulevard
Dallas, TX 75390
Jeffrey L. Elliott, MD Codirector & ALS
Ctr Director
Sharon Nations, MD Codirector
Gil I. Wolfe, MD Codirector

Cook Children's Medical Center
Neurology Department
901 Seventh Avenue, Ste. 120
Ft. Worth, TX 76104
Warren A. Marks, MD Director

Neurology Associates of Arlington
1001 Waldrop, Ste.#816
Arlington, TX 76011
Robert E. McMichael, MD Director

Metroplex Research Grants



University of Texas Southwestern Medical Center

Steve Cannon, MD **\$201,788**

Summary: Researchers will develop a mouse model of periodic paralysis to understand the ion channel functions in these disorders.

Jeffrey Elliot, MD **\$430,167**

Summary: Mutations in the superoxide dismutase (SOD1) gene cause one form of familial ALS in humans as well as in transgenic mice. We previously found that the disease can be markedly accelerated in G93A SOD1 mutant mice by the over-expression of another protein called copper chaperone for SOD1 (CCS). Disease onset is 7 days rather than 6 months, and this acceleration is accompanied by marked changes in the mitochondria, the "powerhouse" of the cell. In this study we will determine whether the effect of CCS on disease is dependent on the specific SOD1 mutation, and if so, what accounts for that difference.

Woodring Wright, MD **\$200,000**

Summary: We have successfully immortalized adult skeletal myoblasts by introducing telomerase, an enzyme that prevents the telomere shortening that is normally used to count cell divisions. Our long-term goal is to create a universal donor that expresses molecules that prevent the cells from dying during the immediate post-transplantation period, maintains them transiently in a proliferative and migratory state, and which express dystrophin and factors that stimulate muscle hypertrophy.

Total Grants: \$831,955

For more information phone (972) 480-0070.